156 related articles for article (PubMed ID: 15232793)
21. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
23. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.
Al-Hejaili F; Kortas C; Leitch R; Heidenheim AP; Clement L; Nesrallah G; Lindsay RM
J Am Soc Nephrol; 2003 Sep; 14(9):2322-8. PubMed ID: 12937309
[TBL] [Abstract][Full Text] [Related]
24. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
[TBL] [Abstract][Full Text] [Related]
26. Treatment of uraemic hyperphosphatemia with calcium acetate: a safe alternative to calcium carbonate.
Biagini M; Malaguti M; Sicoli R; Capece R; Friggi A; Ciaffi G; Bargagna R
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1193-9. PubMed ID: 1457693
[TBL] [Abstract][Full Text] [Related]
27. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study.
Schaefer K; Scheer J; Asmus G; Umlauf E; Hagemann J; von Herrath D
Nephrol Dial Transplant; 1991; 6(3):170-5. PubMed ID: 1866045
[TBL] [Abstract][Full Text] [Related]
28. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.
Tzanakis IP; Papadaki AN; Wei M; Kagia S; Spadidakis VV; Kallivretakis NE; Oreopoulos DG
Int Urol Nephrol; 2008; 40(1):193-201. PubMed ID: 18193489
[TBL] [Abstract][Full Text] [Related]
29. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
30. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
31. Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis.
Wang Y; Xie G; Huang Y; Zhang H; Yang B; Mao Z
PLoS One; 2015; 10(3):e0121376. PubMed ID: 25799184
[TBL] [Abstract][Full Text] [Related]
32. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Finn WF;
Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
[TBL] [Abstract][Full Text] [Related]
33. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients.
Caravaca F; Santos I; Cubero JJ; Esparrago JF; Arrobas M; Pizarro JL; Robles R; Sanchez-Casado E
Nephron; 1992; 60(4):423-7. PubMed ID: 1584317
[TBL] [Abstract][Full Text] [Related]
34. Calcium ketovaline as new therapy for uremic hyperphosphatemia.
Schaefer K; von Herrath D; Erley CM; Asmus G
Miner Electrolyte Metab; 1990; 16(6):362-4. PubMed ID: 2089249
[TBL] [Abstract][Full Text] [Related]
35. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
Ben Hamida F; el Esper I; Compagnon M; Morinière P; Fournier A
Nephron; 1993; 63(3):258-62. PubMed ID: 8446261
[TBL] [Abstract][Full Text] [Related]
36. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
37. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis.
Toussaint N; Boddington J; Simmonds R; Waldron C; Somerville C; Agar J
Hemodial Int; 2006 Jul; 10(3):280-6. PubMed ID: 16805890
[TBL] [Abstract][Full Text] [Related]
38. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients.
Ashurst Ide B; Dobbie H
J Ren Nutr; 2003 Oct; 13(4):267-74. PubMed ID: 14566763
[TBL] [Abstract][Full Text] [Related]
39. Calcium balance and intact PTH variations during haemodiafiltration.
Argilés A; Mion CM
Nephrol Dial Transplant; 1995 Nov; 10(11):2083-9. PubMed ID: 8643172
[TBL] [Abstract][Full Text] [Related]
40. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
Sechet A; Hardy P; Hottelart C; Rasombololona M; Abighanem O; Oualim Z; Brazier M; Achard JM; Pruna A; Moriniere P; Fournier A
Artif Organs; 1998 Jul; 22(7):564-8. PubMed ID: 9684692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
